Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Company Profile and bullboard matches:

IFLM
Sort by: Date|Relevance

Aquestive Therapeutics Shares Up on Pipeline Update and Raised Full-Year 2019 Guidance

Aquestive Therapeutics shares traded 20% higher today after the firm reported Q3/19 earnings and raised its FY/19 guidance. The firm states it expects to complete its NDA for Libervant buccal film near the end of this month. Yesterday afternoon, specialty pharmaceutic...

Own Them All - The Next Media Juggernaut

Since its release in 2009, James Cameron’s Avatar has held the all-time box office record for nearly a decade. With a budget of $300 million and an additional $150 million for marketing, Avatar’s total cost of $450 million was made back several times. The big...

'Undervalued' Biopharma Features Robust Pipeline, Future Upside

The case for investing in this company was made in an H.C. Wainwright & Co. report. In an April 22, 2019 research note, analyst Ram Selvaraju reported that H.C. Wainwright & Co. initiated coverage on Aquestive Therapeutics Inc. (AQST:NASDAQ) , "an undervalued spec...

The Golden Bullet for Drug Delivery

It’s the Holy Grail in the cannabis industry. Everyone is trying to innovate the best delivery system to optimize the “bioavailability” (uptake) of medical cannabis in order to offer the perfect pairing -- precise dosing with a fast on...

Gilead, Teva, XPhyto - Global marketing potential

The best business models solve problems and are scalable. In this context, the healthcare sector is particularly interesting. The world's population has recently reached 7.8 billion people and for this reason solutions can meet a large potential market with users. Cross-border...

XPhyto: The Cutting Edge of Medical Cannabis Science

At the forefront of the next wave of cannabis commercialization, is a German-focused company with headquarters in Vancouver, XPhyto Therapeutics Corp. (CSE: XPHY; FSE: 4XT) , that is building a much-coveted cannabis R&D cultivation facility in a converted nuclear bunker and o...

Buzz on the Bullboards: Hot Summer Stocks Ahead of the Autumn Rush

(Image via Bombardier Inc.) Investors, our audience, and even some executives regularly visit this site to see how their companies and investing strategies are faring in the community. This week, our highlights go to the newer (and returning) companies that have...

Biopharma's Technology Could Render Drug Suitable for COVID-19 Treatment

How this could be achieved using the proprietary platform of TFF Pharmaceuticals and why it could work are discussed in a ROTH Capital Partners report. In an April 7 research note, ROTH Capital Partners analyst Jonathan Aschoff discussed the potential of app...

Deer Horn Moves Toward Tellurium Production

I first wrote about Deer Horn Capital Inc. (DHC:CSE; GODYF:OTCBB) back in January of this year. The company has a primary tellurium project in northern British Columbia, one of only four primary mines in the world. Tellurium is an interesting metal used primarily i...

Buzz on the Bullboards: More tricks than treats in today’s stock market?

It has been an uneasy week for markets on Bay Street and Wall Street. After the TSX hit a two-week low a few days ago, the Bank of Canada voted to keep interest rates at 5 per cent, kicking off a risk rally. U.S. markets have also fared well as optimism grows that...
1 2 3 4 5 6 7 8 9 10 ...